James Crosby

Commissioning Team Manager - Medicine and Health Journals Taylor & Francis

Opinions are my own

[James Crosby @Jamesac19]

@robben_island can you confirm whether today's trips are running? They were cancelled yesterday.

[Journal of Medical Economics @JME_Journal]

Delighted to share that the 𝐉𝐨𝐮𝐫𝐧𝐚𝐥 𝐨𝐟 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜𝐬 is partnered with the 𝐖𝐨𝐫𝐥𝐝 𝐄𝐏𝐀 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 in 2025. To discover more about the conference use the link below 👇
https://t.co/F6CSxgZXk6
#healtheconomics #medicaleconomics #HEOR #RWE

[T&F Medicine & Healthcare @tandfmedicine]

Today we are welcoming ASN Neuro to the T&F Neurology journals portfolio! 🥳
https://t.co/9D8yG5IReX
@ASNeurochem #ASNeuro

[Journal of Medical Economics @JME_Journal]

🚨New Supplement🚨

Delighted to announce publication of our latest supplement on #SystemicLupusErythematosus. Click the link below for full access to the articles 👇

https://t.co/EVRm0Z39pz

#HEOR #healtheconomics #pharmacoeconomics #healthcare

[May Baker @MayBakerEditor]

The special focus issue on Anticoagulation in Expert Review of Cardiovascular Medicine is now live! 📚

Dive into the latest advancements and perspectives in the world of anticoagulation🩸👇

#CardiovascularMedicine #Anticoagulation #ExpertReview

https://t.co/Ga0eZY1nCj

[May Baker @MayBakerEditor]

📢New article alert!

I sat down with @drflett to discuss #heartfailure in the UK. He shares his expertise on treatment, cardiac devices and future outlooks...a must-read for anyone interested in #cardiovascular health! 💙

Read the interview for free 👇
https://t.co/F1OoHgyjY8

[Expert Review of Vaccines @ExpRevVaccines]

Follow @ExpRevVaccines

[Liam François-Hobbins @LiamHobbins]

📢 2 weeks remaining to submit your application for the Editor-in-Chief position of #ExpertOpiniononOrphanDrugs 📢

[Taylor&Francis News @tandfnewsroom]

Elevated Lipoprotein(a) is the latest variant of ‘bad cholesterol’ found to increase the risk of recurrent coronary heart disease.

Findings, published by @UNSWMedicine researchers in @CMRO_Journal, show it is an important CHD predictor in people 60+⚠️
https://t.co/VEtJdEtW2b

[UNSW Medicine & Health @UNSWMedicine]

Elevated bloodstream levels of a ‘bad cholesterol’ variant called Lipoprotein(a) have been identified as a risk factor for recurrent coronary heart disease in people aged 60+, in a new longitudinal study led by @UNSW A/Prof. Leon Simons:
https://t.co/FWE9IgL1OP

[PostgraduateMedicine @postgradmed]

🚨 New special issue now online 🚨

Read our latest special issue, which delves further into the different aspects surrounding #Vasculitis. The issue is freely available for everyone to read until next month.

Click here to read the full articles now ➡️ https://t.co/cuNRgs7SS1

[Journal of Medical Economics @JME_Journal]

🚨Special issue update🚨

We have released the first article online titled "Advancing towards a worldwide #healthcare system in the post #COVID19 era: benefits and barriers to international collaboration in healthcare".

Available here 👉 https://t.co/tZXaQD0Lvg
#Healtheconomics

[Liam François-Hobbins @LiamHobbins]

Looking forward to heading to Glasgow for #WCP2023 in a months time 💊

Please reach out if you would like to discuss the #ExpertCollection journals, #AcceleratedPublication and/or #PlainLanguageSummaries that Taylor & Francis Group has to offer 👋

https://t.co/ekqVHsCtZH

[Journal of Medical Economics @JME_Journal]

ISPOR 2023, the leading global conference for health economics and outcomes research (#HEOR), May 7-10 at the Boston Convention & Exhibition Center, Boston, MA, USA. Hear the latest hot topics and trends in #HEOR. #ISPORAnnual

Click the link for more 👉 https://t.co/mCrgrlMmfD

[Journal of Medical Economics @JME_Journal]

ISPOR 2023, the leading global conference for health economics and outcomes research (#HEOR), May 7-10 at the Boston Convention & Exhibition Center, Boston, MA, USA. Hear the latest hot topics and trends in #HEOR. #ISPORAnnual

click the link for more 👉https://t.co/mCrgrlMmfD

[Sophia Aldwinckle @SophiaAldw]

🚨 How can digital endpoints empower patients? 🚨
WELCOMING SUBMISSIONS at Expert Review of Pharmacoeconomics & Outcomes Research in collaboration with Guest Advisor Katarzyna Kolasa.
👇 Learn more at the link below 👇 #digitalhealth
https://t.co/7Ricy87xk8

[PostgraduateMedicine @postgradmed]

Delighted to share a recent supplement, which has been published in Postgraduate Medicine, on "#Semaglutide for #weight management – an introduction for primary care."

Click here to read the full supplement ➡️ https://t.co/dIGxwbnpyK #WeightManagement #Obesity #PrimaryCare

[James Crosby @Jamesac19]

#RBX2660 a promising treatment for recurrent C.diff has recently gained #FDA approval. This first-in-class microbiota-based live biotherapeutic has huge potential. Drug profile free to read here:https://t.co/idRerwtcWj
Editorial free to read here:https://t.co/iHGfKRcWX0

[Sophia Aldwinckle @SophiaAldw]

We are excited to share this special focus issue on JAK inhibitors in autoimmune and inflammatory diseases in Expert Review of Clinical Immunology #immunology #rheumatology #jakinhibitors
https://t.co/Mvoo3P2KiU

[Journal of Medical Economics @JME_Journal]

To start we would love to know what field you work in to establish who is benefiting most from the 2022 CHEERS statement. Please select one of the options or leave a comment below. #JMECHEERS2022

View the statement here 👉 https://t.co/s5BHuFrjKx